The erbB 2 oncogene and chemotherapy: A mini-review

Journal of Chemotherapy

Volumn 9, Issue 1, 1997, Pages 51-55

  Torre, E A ^a   Salimbeni, V ^a   Fulco, R A ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

drug resistance; erB 2; oncogene

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; GENE EXPRESSION; HUMAN; LUNG CANCER; ONCOGENE;

EID: 0030964789     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.1.51     Document Type: Article

References (46)

1. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 ; 323: 561-565.
2. Mitsudomi T, Sreinberg SM, Oie HK, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999-5002.
3. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990 ; 50: 5184-5187.
4. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erb B-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27: 1372-1375.
5. Niimi S, Nakagawa K, Yokota J, et al. Resistance to anti-cancer drugs in NIH3T3 cells transfected with c-myc and /or c-H-ras genes. Br J Cancer 1991; 63: 237-241.
6. Sklar MD. Increased resistance to cis-diamminedichloroplatinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 1988 ; 48: 793-797.
7. Toffoli G, Viel A, Tumiotto L, Buttazzi P, Biscontin G, Baiocchi M. Sensitivity pattern of normal and Ha-ras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori 1989 ; 75: 423-428.
8. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993; 53: 4443-4448.
9. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648-3654.
10. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Sem Oncol 1989; 16(2): 156-65.
11. Foekens JA, Schmitt M, van Putten WL, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
12. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine Kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
13. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinogen 1992; 5: 213-218.
14. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King R, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178-181.
15. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159-7163.
16. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B-related gene in a human mammary carcinoma. Science 1985; 229 : 974-976.
17. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor related proto-oncogcne erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987; 6: 605-610.
18. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbR-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-2023.
19. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461.
20. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990 ; 50: 4087-4091.
21. Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985 ; 82: 6497-6501.
22. Yokota T, Yamamoto T, Miyajima N, et al. Genetic alterations of c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988; 2: 283-287.
23. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer. Prognostic significance of over-expression influenced by presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
24. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer: J Clin Oncol 1992;10: 1049-1056.
25. Muss H, Thor A, Kute T, et al. ErbB-2 (c-erbB-2: HER-2/neu) and S-phase fraction predict response to adjuvant chemotherapy in patient with node-positive breast cancer: Cancer and Acute Leukemia Group B Trial 8869. Proc ASCO 1993; 12: 72.
26. Muss H, Thor A, Berry D, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
27. Paik S. Clinical significance of erbB-2 (ErbB 2) protein. Cancer Invest 1992; 10(6): 575-579.
28. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H. ErbB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994 ; 81, 2: 137-44.
29. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10, 12: 2435-46.
30. Chun-Ming T, Kuo-Ting C, Reury-Perng P, Tetsuya M, Mei-Hui C, Chikabumi K, Adi FG. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with ErbB 2 gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901.
31. Gazdar AF. Pathologic and clinical relevance of molecular genetic changes in lung cancer. Proc Annu Meet Am Assoc Cancer Res 1992; 33: A606-7.
32. Tsai CM, Chang KT, Wu LH, et al. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cancer cell lines. Cancer Res 1996; 56,1: 206-9.
33. Lai SL, Goldsten LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 1989; 81: 1144-1150.
34. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and revision of the transformed phenotype by monoclonal antibodies. Cell 1985 ; 41: 695-706.
35. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. Monoclonal antibody has antiproliferative effect in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
36. Hancock MC, Langton BC, Chan T, Toy P, Monathan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell. Cancer Res 1991; 51: 4575-4580.
37. Pietras RJ, Scates S, Howell SB, Slamon DJ. Monoclonal antibody to ErbB 2 receptor modulates DNA repair and platinum sensitivity in human breast and ovarian carcinoma cells. Proc Annu Meet Am Assoc Cancer Res 1992 ; 33: A3272.
38. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to Her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9,7: 1829-38.
39. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995; 55,20: 4586-93.
40. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and fc gamma RIII. J Hematother 1995; 4, 5: 453-6.
41. Valone FH, Kaufman PA, Guyre PM, et al. Phase 1A/1B trial of bispecific antibody MDX 210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu. J Clin Oncol 1995; 13,9: 2281-92.
42. Valone FH, Kaufman PA, Guyre PM, et al. Clinical trials of bispecific antibody MDX 210 in women with advanced breast or ovarian cancer that overexpresses Her-2/neu. J Hematother 1995; 4,5: 471-5.
43. Wels W, Beerli R, Hellmann P, et al. EGF receptor and p 185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995; 60,1: 137-44.
44. Jeschke M, Weis W, Dengler W, Imber R, Stocklin E, Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 1995; 60: 730-9.
45. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Nad Acad Sci USA 1992; 89,13: 5867-71.
46. Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 1995; 6,3: 135-45.